| James Farrell, MD | |
|
12605 E 16th Ave, Aurora, CO 80045-2545 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | James Farrell |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609222421 | NPI | - | NPPES |
| Entity Name | University Orthopaedic Services Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578599866 PECOS PAC ID: 7810983004 Enrollment ID: O20040422001292 |
News Archive
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.
Optovue, the company that launched the first FDA cleared fourier/spectral domain OCT in the U.S., announced that it has received 510(k) clearance on its Normative Database ("NDB") for the RTVue OCT device.
A drug that could reduce the harmful side-effects of 'binge drinking', especially by teenagers, has been successfully developed and tested by a team of European scientists, including the University of Huddersfield's Professor Mike Page and Dr Karl Hemming. There is also the potential for new ways to treat Alzheimer's and other neurological diseases that damage the brain.
› Verified 6 days ago
| Entity Name | Erie County Medical Center Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528233616 PECOS PAC ID: 1456308907 Enrollment ID: O20050715000538 |
News Archive
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.
Optovue, the company that launched the first FDA cleared fourier/spectral domain OCT in the U.S., announced that it has received 510(k) clearance on its Normative Database ("NDB") for the RTVue OCT device.
A drug that could reduce the harmful side-effects of 'binge drinking', especially by teenagers, has been successfully developed and tested by a team of European scientists, including the University of Huddersfield's Professor Mike Page and Dr Karl Hemming. There is also the potential for new ways to treat Alzheimer's and other neurological diseases that damage the brain.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Farrell, MD 4225 Genesee St, Ste 400, Cheektowaga, NY 14225-1994 Ph: (716) 906-5908 | James Farrell, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.
Optovue, the company that launched the first FDA cleared fourier/spectral domain OCT in the U.S., announced that it has received 510(k) clearance on its Normative Database ("NDB") for the RTVue OCT device.
A drug that could reduce the harmful side-effects of 'binge drinking', especially by teenagers, has been successfully developed and tested by a team of European scientists, including the University of Huddersfield's Professor Mike Page and Dr Karl Hemming. There is also the potential for new ways to treat Alzheimer's and other neurological diseases that damage the brain.
› Verified 6 days ago
Mr. Philip Adam Stull, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1411 S Potomac St, Ste 400, Aurora, CO 80012 Phone: 303-695-6060 Fax: 303-369-7776 | |
Andrew Maertens, Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 13001 E 17th Pl, Aurora, CO 80045 Phone: 303-724-2963 | |
Peter D'ambrosia, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Mr. Stephen David Lindenbaum, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1411 S Potomac St, Ste 400, Aurora, CO 80012 Phone: 303-695-6060 Fax: 303-369-7776 | |
Dr. Jeffrey Dalton Hassebrock, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1635 Aurora Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Thomas James France, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 13001 E 17th Pl, Aurora, CO 80045 Phone: 303-724-8472 | |
Carissa C Dock, Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 12631 E 17th Ave, Aurora, CO 80045 Phone: 303-724-8472 |